Clinical Trials
22 trialsNCT07005102 2026-05-22
A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
AbbVie
Phase 2/3 Recruiting
NCT06989437 2026-05-20
A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue
Pfizer
Phase 2/3 Recruiting
NCT07112196 2026-05-20
VINCIT
CatalYm GmbH
Phase 2/3 Recruiting
NCT07155187 2026-03-11
A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
AbbVie
Phase 2/3 Recruiting
NCT03435796 2026-03-04
Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells
Celgene
Phase 2/3 Recruiting
NCT07321847 2026-01-07
INJECTABL-3
Immunophotonics, Inc.
Phase 2/3 Not yet recruiting
NCT05694013 2025-10-22
ORIGAMA
Hoffmann-La Roche
Phase 2/3 Terminated
NCT03653546 2025-09-10
BM
Alpha Biopharma (Jiangsu) Co., Ltd.
Phase 2/3 Completed
NCT03470922 2025-09-09
RELATIVITY-047
Bristol-Myers Squibb
Phase 2/3 Active not recruiting
NCT03348670 2025-08-17
Drugs-SNPs
Medicine Invention Design, Inc
Phase 2/3 Active not recruiting
NCT01064466 2025-07-24
Drugs-SNPs
Medicine Invention Design, Inc
Phase 2/3 Active not recruiting
NCT03512756 2024-11-06
A Randomized Phase 2/3 Multi-Center Study of SM-88 in Participants With Metastatic Pancreatic Cancer
Tyme, Inc
Phase 2/3 Terminated
NCT01438112 2021-04-14
BOND
CG Oncology, Inc.
Phase 2/3 Terminated
NCT02910063 2021-01-13
Study to Evaluate Safety and Efficacy of Blinatumomab in Subjects With Relapsed/Refractory (R/R) Aggressive B-Cell NHL
Amgen
Phase 2/3 Completed
NCT04546607 2020-09-16
Evaluation of Clinical Efficacy and Safety of Nuvastatic in Cancer Asthenia
Natureceuticals Sdn Bhd
Phase 2/3 Completed
NCT02186301 2019-05-07
EGFR
Clovis Oncology, Inc.
Phase 2/3 Terminated
NCT02116803 2018-03-01
An Open Label Multi-center Extension Study to Evaluate Long-term Safety/ Tolerability of Dovitinib in Patients With Solid Tumors Who Continue to Receive Treatment With Dovitinib (TKI258) in Novartis-sponsored Single Agent Dovitinib Studies Which Fulfilled the Requirements for the Primary Objective
Novartis
Phase 2/3 Completed
NCT02388919 2017-09-18
ALTER0303
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 2/3 Completed
NCT01185470 2017-04-24
The Clinical Evaluation of Implantable Pump System For Safety And Delivery Accuracy In Patients Requiring Intrathecal Administration Of Morphine Sulfate For Chronic Pain
Medallion Therapeutics, Inc.
Phase 2/3 Completed
NCT00393822 2014-07-15
A Study of Palifermin for the Reduction of Oral Mucositis in Subjects With Stage 2B or 3 Locally Advanced, Colon Cancer
Amgen
Phase 2/3 Completed
NCT00644787 2013-06-13
A Dose-Finding Study of Fentanyl (JNS020 QD) 1-Day Transdermal Patch in Participants With Cancer Pain
Janssen Pharmaceutical K.K.
Phase 2/3 Completed
NCT00758407 2010-01-13
EMF
Medice Arzneimittel Pütter GmbH & Co KG
Phase 2/3 Completed